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Despite the known heterogeneity of type 2 diabetes and
variable response to glucose lowering medications, cur-
rent evidence on optimal treatment is predominantly
based on average effects in clinical trials rather than
individual-level characteristics. A precision medicine
approach based on treatment response would aim to
improve on this by identifying predictors of differential
drug response for people based on their character-
istics and then using this information to select optimal
treatment. Recent research has demonstrated robust
and clinically relevant differential drug response with
all noninsulin treatments after metformin (sulfonyl-
ureas, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4]
inhibitors, glucagon-like peptide 1 [GLP-1] receptor
agonists, and sodium–glucose cotransporter 2 [SGLT2]
inhibitors) using routinely available clinical features. This
Perspective reviews this current evidence and discusses
how differences in drug response could inform selection
of optimal type 2 diabetes treatment in the near future. It
presents a novel framework for developing and testing
precision medicine–based strategies to optimize treat-
ment, harnessing existing routine clinical and trial data
sources. This framework was recently applied to dem-
onstrate that “subtype” approaches, in which people
are classified into subgroups based on features reflect-
ing underlying pathophysiology, are likely to have less
clinical utility compared with approaches that combine
the same features as continuous measures in probabi-
listic “individualized prediction” models.
Type 2 diabetes is a complex disease, characterized by
hyperglycemia associated with varying degrees of insulin
resistance and impaired insulin secretion and influenced
by nongenetic and genetic factors. Despite this, glucose-
lowering treatment is similar for most people. Current
type 2 diabetes guidelines recommend the choice between
glucose-lowering treatment options is based on clinical
characteristics (1), an approach in line with the central goal
of precisionmedicine: the tailoring of medical treatment to
an individual. After initial metformin, the most recent
guidelines recommend glucagon-like peptide 1 receptor
agonists (GLP-1RA) or sodium–glucose cotransporter
2 inhibitors (SGLT2i) in people with established ath-
erosclerotic cardiovascular disease, heart failure, or chronic
kidney disease, but this stratification only applies to up to
15–20% of people with type 2 diabetes (2,3). For the
remaining majority, evidence of benefit beyond glucose
lowering with these drug classes has not been robustly
demonstrated, and the optimal treatment pathway is not
clear (1). Evidence on the key considerations, notably
glucose-lowering efficacy, tolerability, and side effects, is
mainly derived from average treatment effects from clin-
ical trials. This means there is little information available
on whether a specific person in the clinic is more or less
likely than the average trial participant to respond well to
a particular treatment or develop side effects. Given this
knowledge gap, there is currently great interest in de-
veloping approaches that can characterize people beyond
the standard type 2 diabetes phenotype and use this het-
erogeneity to optimize the selection of glucose-lowering
treatment.
Any successful implementation of precision medicine in
type 2 diabetes is likely to be very different from the most
successful examples of precision medicine to date. These
have been in cancer and single-gene diseases such as mono-
genic diabetes, where expensive genetic testing defines the
etiology and the specific etiology helps to determine treat-
ment (4,5). In type 2 diabetes, unlike cancer, tissue is not
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available, and unlike rare forms of diabetes, current genetic
testing does not allow clear definition of the underlying
pathophysiology (6). This makes identification of discrete, non-
overlapping subtypes of type 2 diabetes much less likely (7).
In this Perspective, I focus on a fundamental aim of
precision medicine—the selection of optimal type 2 diabe-
tes treatment based on likely differences in drug effect
(henceforth, heterogeneity of treatment effect [HTE]). I
provide an overview of the evidence from recent studies of
HTE in type 2 diabetes and present a framework for using
existing routine clinical and trial data sources to develop
and test precision medicine–based strategies to optimize
treatment. The focus is on glycemic response, as nearly all
current evidence of HTE for diabetes drugs is for differ-
ences in HbA1c. However, the framework outlined can
easily be extended to evaluate HTE for nonglycemic end
points, including microvascular and macrovascular com-
plications. Type 2 diabetes is a highly prevalent condition
with relatively inexpensive treatment, meaning precision
medicine approaches based on inexpensive markers have
greatest potential to translate into clinical practice in the
near future. As a result, this article concentrates on the
use of routinely available clinical features to select opti-
mal treatment, although the principles discussed equally
apply to the use of genomic or nonroutine biomarkers (6).
Recent reviews of the pharmacogenomics of type 2 di-
abetes drug response are available elsewhere (8,9).
Why Type 2 Diabetes Glucose-Lowering Treatment Is
an Excellent Candidate for a Precision Medicine
Approach
Type 2 diabetes treatment is an excellent candidate for
a precision medicine approach for the following reasons. 1)
There are many different drug classes available after met-
formin with different mechanisms of action but the same
principal aim: to lower blood glucose. 2) At the individual
level, glucose-lowering response to each drug appears to
vary greatly (Fig. 1). 3) There is not a clear “best” overall
treatment outside a small proportion of individuals with
specific complications. For the remainder, current treat-
ment guidelines do not provide information on which drug
class is best for lowering blood glucose, for which people (1).
4) There is great heterogeneity in the clinical phenotype of
type 2 diabetes, making it plausible that people with dif-
ferent underlying pathophysiology will have varying responses
to the different drug classes, depending on the mechanism of
action of the drug.
Defining the Treatment Selection Approach in
Type 2 Diabetes
Despite the large biological noise in HbA1c, the majority of
people appear to respond when initiated on a glucose-
lowering drug (Fig. 1), and it is unlikely that many who
appear not to respond are true “nonresponders” (10).
Therefore, the aim of precision medicine in type 2 di-
abetes is not to identify people who will and will not
respond (which can only be achieved through repeated
crossover trial designs [11,12]) but instead to identify
people who are likely to have a greater relative benefit
from one drug class over another. This means that the
necessary first step is to identify whether there are markers
robustly predictive of greater or lesser response to each
drug class to a clinically significant degree. In the absence
of single markers with huge effect sizes, which have not
been found to date, the second step is to optimally use
multiple markers in combination to select treatment for
individuals.
Identifying Robust Predictors of Type 2 Diabetes
Treatment Response Using Routine and Trial Data
A focus on identifying routine clinical markers means HTE
can be evaluated using existing observational and trial data
sets that capture information on the drug response of
people initiating type 2 diabetes treatment. The conven-
tional approach is to examine HTE in clinical trials using
“one-at-a-time” subgroup analysis in which participants
are subcategorized based on a set of single characteristics
in turn, such as sex and age (old vs. young). This approach
does not provide credible evidence of differences in re-
sponse due to low statistical power, lack of multivariable
adjustment, and the risk of false-negative and false-positive
findings (13). This means very few “discovered” positive
subgroups are subsequently replicated (14,15).
While subgroup analysis of trials is limited, a combina-
tion of large observational routine clinical data sets and
trial data (increasingly available [16,17]) provides a power-
ful starting point to robustly evaluate HTE. Large anony-
mized routine clinical electronic health record databases,
such as the U.K.’s Clinical Practice Research Datalink (18),
provide a rich source of “real-world” information on de-
mographics, clinical features, diagnoses, laboratory tests,
and prescriptions. One two-step approach to “triangulate”
routine and trial data sources is shown in Fig. 2, on the
basis that the best evidence for robust HTE is replication of
effect in multiple independent data sets with differing
strengths and weaknesses. In step 1, due to the large sample
size and availability of head-to-head data for all drug classes,
routine clinical data are used for “discovery” analysis, with
assessment of drug-by-marker interactions to identify can-
didate features associated with differential response across
drug classes. As in these observational data drug selection is
not random and there are likely to be large differences in
baseline clinical features between treatment groups, careful
identification of confounders and statistical adjustment is
required. To further reduce bias, the use of causal inference
methods such as inverse probability of treatment weighting
(19), or target trial approaches where studies are set up to
emulate the design of an “ideal” randomized trial, should be
considered (20). Nonetheless, unmeasured confounding may
still bias findings, meaning a second step of external valida-
tion is required to confirm findings. In step 2, specific markers
associated with potentially clinically relevant differences in
drug response can be tested for reproducibility as prespeci-
fied hypotheses in clinical trial data sets where treatment
allocation is randomized and blinded and where there is
2076 Precision Medicine in Type 2 Diabetes Diabetes Volume 69, October 2020
systematic baseline assessment and follow-up, meaning the
risk of confounding is much lower (21). This two-step ap-
proach takes advantage of the larger, more heterogeneous
population in routine care data sets for feature discovery while
minimizing the risk of data mining in the smaller, richer trial
data sets.
What Clinical Features Alter Type 2 Diabetes Treatment
Response?
Recent studies have demonstrated clinically relevant dif-
ferences in response by clinical features for all noninsulin
glucose-lowering drug classes commonly used after met-
formin. Studies that do not adjust for baseline HbA1c are
not reported here, given the demonstrated risk of false
associations in such analysis (22).
Sulfonylurea and Thiazolidinedione Treatment
The first robust demonstration of HTE for type 2 diabetes
therapy used the routine and trial data framework pre-
viously described to evaluate differential response to sul-
fonylurea (SU) and thiazolidinedione (TZD) treatment.
Observational data from U.K. primary care data were
used as a discovery data set, in which it was demonstrated
that males without obesity (BMI ,30) have on average
a greater glucose-lowering response with SU compared
with TZD treatment, while, conversely, females with
obesity (BMI $30) have a greater response to TZD
than SU treatment (21). Differences in response in these
subgroups were then validated, and confirmed to hold
for long-term response, in randomized trial replication
data, with differences in effect size within these sub-
groups equivalent to the addition of another glucose-
lowering treatment (Fig. 3).
Dipeptidyl Peptidase 4 Inhibitors and GLP-1RA
With dipeptidyl peptidase 4 inhibitors (DPP-4i), the pro-
spective Predicting Response to Incretin Based Agents
(PRIBA) study demonstrated that markers of higher in-
sulin resistance are consistently associated with lesser
glucose-lowering response in non–insulin-treated partic-
ipants (23). Differences were clinically relevant; a sub-
group defined by obesity (BMI $30) and high triglycerides
($2.3 mmol/L) (31% of participants) had a response less
than half that of a nonobese, low triglyceride (,2.3 mmol/L)
subgroup (22% of participants) (6-month response 25.3
mmol/mol [20.5%] and 211.3 mmol/mol [21.0%], re-
spectively). Conversely, there was no evidence of an
association between markers of insulin resistance and
glucose-lowering response for non–insulin-treated people
initiating GLP-1RA (Fig. 4). Results were replicated in U.K.
primary care data. Interestingly, in insulin-treated peo-
ple but not in non–insulin-treated people, the same study
found that with GLP-1RA, clinical markers of low b-cell
function such as lower C-peptide and longer duration of
diabetes were associated with reduced glucose-lowering
efficacy (24). With DPP-4i, several other studies sup-
port the association between lower BMI, lower insulin
resistance, and greater response and also suggest a ben-
efit in glucose-lowering for people of Asian ethnicity
(25,26).
SGLT2i
Analysis of trial data have reported markedly greater
relative benefit with SGLT2i at higher baseline HbA1c
levels compared with DPP-4i or SU treatment (27,28).
Differences in response with SGLT2i have also been ob-
served by baseline renal function. While the reduced efficacy
Figure 1—Themarked individual-level variation in change in HbA1c at 6months (6-month HbA1cminus baseline HbA1c) by drug in the ADOPT
trial for 3,707 participants with a valid measure of HbA1c at 6 months. A negative change is represented an improvement in HbA1c. Mean (SD)
improvement in HbA1c was greatest at 6 months for SU29.4 (8.6) mmol/mol [0.9%], compared with metformin27.5 (8.1) mmol/mol [0.7%]
and TZD treatment 26.4 (8.6) mmol/mol [0.6%].
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of SGLT2i at estimated glomerular filtration rates (GFRs)
,60 mL/min/1.73 m2 is well established (29), pooled trial
analysis has demonstrated that this likely extends across the
normal range, meaning that people with baseline eGFR
.90 mL/min/1.73 m2 have a greater response compared
with those with eGFR 60–90 mL/min/1.73 m2 (30). In con-
trast, with DPP-4i, response is likelymaintained in people at
lower eGFRs (31). Early work by our group suggests that
these differential treatment effects for SGLT2i and DPP-4i
are replicated in U.K. primary care data (Fig. 5).
Figure 3—Five-year glycemic response (change from baseline in HbA1c) with TZD and SU treatment in males without obesity (BMI,30) (A)
and females with obesity (BMI$30) (B) subgroups in 1,232 participants in the ADOPT clinical trial (21). Data are presented as means6 SD at
each study visit frommixed-effectsmodels. A reduction (improvement) in HbA1c is represented as a negative value. For area-under-the-curve
(AUC) difference estimates, positive values favor SU, and negative values favor TZD. Adapted from Dennis et al. (21).
Figure 2—A “triangulation” approach using routine clinical and trial data to evaluate differences in drug response, and the strengths and
weaknesses of each data source.
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Factors Altering Treatment ResponseMayRelate to the
Underlying Mechanism of Action of Different Drug
Classes
The identified clinical features associated with HTE in
many cases relate to the known mechanisms of action of
the different drug classes. Such “plausibility of effect
modification” greatly strengthens the credibility of HTE
analysis (13). For TZD, in addition to the increased insulin
resistance with higher BMI, variation in response by sex and
obesity is likely to reflect associated differences in adipocyte
distribution and function, as these drugs primarily act on
adipose tissue (32,33). For SU and DPP-4i, which stimulate
insulin secretion by the b-cell, the association between
reduced insulin sensitivity and higher BMI possibly explains
greater response in nonobese people. However, this does
not explain the lack of association between insulin resis-
tance and glucose lowering for the other incretin-based drug
class, GLP1-RA; it is possible this difference could relate to
the added weight-loss effects of this medication class or that
GLP-1RA response was studied in an almost entirely obese
(and therefore insulin resistant) population (23). The lack of
GLP-1RA glycemic benefit in insulin-treated participants
with very severe endogenous insulin deficiency is also
consistent with the known role of potentiation of endog-
enous insulin secretion in their action. Effects on urinary
glucose excretion provide a likely explanation for the var-
iation in glucose-lowering efficacy of SGLT2i with baseline
HbA1c and eGFR (30,31).
How Can Differences in Treatment Response Inform
Selection of Optimal Treatment?
While evidence of robust differences in type 2 diabetes
treatment response is growing, there is current debate and
considerable uncertainty about how to translate this to
inform decision-making in clinical practice. Recent litera-
ture has focused on the following two approaches (Fig. 6).
The first approach is a “subtypes” approach, in which
people with type 2 diabetes are subclassified based on their
underlying pathophysiology (whether clinical, genetic, phe-
notypic, or biomarker traits) on the assumption that once
subtypes are defined, they will have utility to stratify ther-
apeutic decisions and other outcomes such as progression to
complications. This was recently and notably proposed by
Ahlqvist et al. (34) in a sex-stratified, data-driven cluster
Figure 4—Associations between markers of insulin resistance and HbA1c response with DPP-4i and GLP-1RA treatment in the PRIBA study
(n 5 593), in participants not on insulin cotreatment. Estimates denote the mean HbA1c change (mmol/mol) at 6 months (baseline HbA1c
minus 6-month HbA1c) per 1-SD higher baseline value of each marker. Associations were tested in a series of independent linear regression
models adjusted for baseline HbA1c and cotreatment change. Error bars denote 95%CI. Adapted from Dennis et al. (23). HOMA2-IR, HOMA
of insulin resistance; SHBG, sex hormone binding globulin; UCPCR, urine C-peptide creatinine ratio.
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analysis of people close to diabetes diagnosis that grouped
individuals with similar underlying pathophysiology using
five clinical features (age at diagnosis, BMI, HbA1c, and
HOMA-measured insulin resistance and insulin sensitivity)
in Scandinavian registry data. Importantly, similar-looking
subgroups were identifiedwhen the analysis was repeated in
multiple international population-based cohorts (35,36).
Subgroups showed differences in outcomes in observa-
tional follow-up, although differential treatment response
was not assessed. Several other data-driven classifications
have recently been proposed with substantial variation in
the features used for classification and the numbers of
subgroups identified (37–39), including genetically de-
fined clusters (40,41), but their utility to stratify treat-
ment response has similarly not been assessed.
The second approach is to use a person’s specific clinical
information in a probabilistic “individualized prediction”
approach. In this approach, markers reflecting underlying
pathophysiology are used as continuous traits to directly
predict an individual’s treatment response for each drug.
An individual’s specific information can then be used to
predict their likely best drug in terms of glucose-lowering
response (or, alternatively, to identify the absence of clin-
ically relevant differences in response across treatments),
and these predictions can guide selection of optimal treat-
ment. The model developed is specific to the outcome of
treatment response and can be deployed based on a person’s
current information at the point a decision to escalate
treatment is made. Although subtypes could then in theory
be specified based on the prediction of differential response
or optimal therapy, this would make little sense, as the
subtypes would be based on clinical parameters that vary
over time and are affected by treatment, meaning that for
an individual, subtype assignment is unlikely to be stable.
This proposed approach is consistent with the ideas un-
derlying the recently proposed “palette model” of diabetes
(7), which, at a specific point in time, positions an individual
with diabetes on a spectrum of phenotypic variation and
uses this position to predict likely outcome.
While the advantages and disadvantages of each ap-
proach in the context of selecting optimal treatment are
shown in Fig. 6, the fundamental difference between the
two approaches is that the subtypes approach assumes
homogeneity of differential treatment response for all indi-
viduals within a subtype, whereas the individualized pre-
diction approach allows for estimation of differential treatment
effects at the individual level. The use of individual-level
data means that the individualized prediction approach
will almost certainly provide more precise estimates of
treatment response, and thus more accurately guide op-
timal treatment selection, than approaches that lose in-
formation by classifying individuals into subgroups (42).
The same principles will apply to prediction of any other
outcome, for example, predicting disease progression or de-
velopment of microvascular and macrovascular complications.
Evaluating Performance of Strategies for Selecting
Optimal Treatment
Our group has recently applied a novel framework to
evaluate treatment selection models in type 2 diabetes.
Novel approaches are required in this context; conven-
tional measures of prediction model performance are of
Figure 5—Associations between baseline HbA1c and baseline eGFR (Chronic Kidney Disease Epidemiology Collaboration formula) and
HbA1c response at 6 months (baseline HbA1c minus 6-month HbA1c) with SGLT2i and DPP-4i treatment in U.K. primary care data (Clinical
Practice Research Datalink) (n5 20,965). Results are predicted values from a linear regression model including baseline HbA1c-by-drug and
eGFR-by-drug interaction terms (with each modeled as a restricted cubic spline with 3 knots), with additional adjustment for number of
diabetes treatments ever initiated, number of current diabetes treatments, age at treatment, duration of diabetes, sex, and BMI. Gray shading
represents 95% CI. A: Baseline HbA1c. B: Baseline eGFR.
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limited utility when evaluating treatment selection mod-
els (13), as the focus is not the overall ability of a model to
predict response but rather accurate identification of
treatment-by-covariate interactions that predict differ-
ences in response between treatments. At the individual
level these differences are unobservable (13), as at one
point in time the response of a person to multiple
different therapies cannot simultaneously be evaluated.
Our framework was applied to test head-to-head the
Ahlqvist clusters strategy against an individualized pre-
diction strategy for selecting optimal treatment, in post
hoc analysis of individual level data from two large clinical
trials (A Diabetes Outcome Progression Trial [ADOPT] and
Rosiglitazone Evaluated for Cardiac Outcomes and Regu-
lation of Glycaemia in Diabetes [RECORD]; n 5 8,798)
(43–45). This was important, as a key discussion point
raised in the Ahlqvist et al. study was that the clusters
identified could be used to “guide therapy” (34). In both
trials, participants were randomized to either SU, TZD, or
metformin treatment. The same five subtypes proposed
using the Scandinavian data were reproduced in ADOPT
using the same data-driven cluster analysis approach
Figure 6—Individualized prediction compared with classification into subtypes: advantages and disadvantages of two strategies to apply
a precision medicine approach in type 2 diabetes. A) Classification into subtypes. B) Individualized prediction.
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(34,46). Then, within each subtype, average glycemic
response for each of the three treatments was estimated,
and the treatment associated with the greatest average
glycemic response was allocated as the optimal treatment
for all people assigned to that subtype. The utility of the
subtypes was compared with an individualized prediction
strategy that assigned optimal treatment on an individual
rather than subtype level, using a model that estimated
response for each drug for each participant based on their
specific features. Notably, only the simple routine clinical
features (sex, and BMI, HbA1c, and age at diagnosis as
continuous markers) were used for the individualized pre-
diction model; two features used to inform the cluster
analysis, HOMA-IR and HOMA-B (respectively, measures
of insulin resistance and insulin secretion), were not in-
cluded, as they are not routinely available in clinical practice.
Despite including only simple markers, the individual-
ized prediction strategy markedly outperformed the sub-
types strategy in the external validation trial data set
(RECORD trial; n5 4,057) (Fig. 7) (43). For each strategy,
the approach used was to define two subgroups of par-
ticipants: 1) a concordant subgroup whose randomized
treatment was the same as their predicted optimal treat-
ment and 2) a discordant subgroup whose randomized
treatment differed from their predicted optimal treat-
ment (47). The difference between the concordant versus
discordant subgroups was then contrasted for each strat-
egy, with a bigger difference indicating a more useful
treatment selection strategy. Where external test data
sets are available, this evaluative framework represents
a novel and cost-effective means of evaluating the utility
of treatment selection models, whether on their own or in
head-to-head comparison, and can be applied for other
outcomes as well as treatment response.
Future Directions: “omics” and Beyond HbA1c
While this Perspective has focused only on glycemic re-
sponse to diabetes treatment, the approaches outlined can
easily be extended to nonglycemic end points including
microvascular and macrovascular complications. The ideal
precision medicine approach in type 2 diabetes will max-
imize therapeutic benefit while limiting risks (48), which
will also require evaluation of HTE for side effects, glyce-
mic progression, and risk of microvascular or macrovas-
cular complications. Particular subgroups at higher risk of
common treatment-specific side effects are already estab-
lished for several drug classes; for example, the risk of
fracture with TZD is limited mainly to females (49), and
with SGLT2i females and those with a history of prior
infection are at greatly increased risk of genital infections
(50). Methods to overcome unmeasured confounding, such
as the prior event rate ratio, may have particular utility for
evaluating side-effect risk in observational routine care data
where allocation to therapy is not randomized (51,52). A
related but overlooked question for precisionmedicine, with
great clinical relevance, is whether the benefits and risks
of a treatment are positively associated. This is likely the
case for TZD; the risk of edema and likelihood of weight
gain increase with greater glucose-lowering response
(21,53), and this should be an important consideration
when choosing treatment. A further extension of the
current work would be evaluation of effects of higher-
order drug combinations. This will be possible in large
routine clinical data sets where substantial numbers of
patients are on specific combination therapies, although
robust validation approaches will be required.
A key question is how genetics can inform precision
medicine in type 2 diabetes. Proposed genetically defined
type 2 diabetes subtypes reflect and help to understand
Figure 7—Three-year glycemic response (change from baseline in HbA1c) with concordant and discordant subgroups using the subtypes
strategy and the individualized prediction strategy in the RECORD trial independent validation set (n5 4,057). Each strategy was developed
in the ADOPT trial (n 5 3,785). Data are presented as means (95% CI) at each study visit from mixed-effects models. A reduction
(improvement) in HbA1c is represented as a negative value. For area-under-the-curve (AUC) estimates, a more negative value represents
a greater response. Adapted from Dennis et al. (43). A: Subtypes strategy. B: Individualized prediction strategy.
2082 Precision Medicine in Type 2 Diabetes Diabetes Volume 69, October 2020
underlying pathophysiology (40,41). The clear advantage
of using genetics is stability, as subtypes defined solely by
genetics will be constant throughout life. At the moment it is
unknown whether the continuous polygenic scores under-
lying genetic subtypes can improve prediction models that
are based solely on routine clinical features and biomarkers.
For treatment response, individual genetic markers have
shown differences for specific treatments and may be of
clinical utility when genetic information is routinely avail-
able in the medical records (54,55). If clinically relevant
benefit can be demonstrated for polygenic scores and
implementation is cost-effective, such scores can similarly
be integrated into models based on routine clinical features.
A further exciting opportunity is the application of causal
inference, data-driven machine learning, and artificial
intelligence–based approaches to improve HTE predic-
tion accuracy and generalizability of findings from large
data sources such as electronic health records. Data-
driven approaches may be of particular utility when data-
bases start to incorporate high-dimensional genetic infor-
mation (56). One possibility is that individualized prediction
models developed with standard statistical methods based on
classical risk factors could be augmented with data-driven
classification approaches, if data-driven approaches are able
to improve prediction by capturing higher-order complex
traits missed by the standard methods.
Although existing data can be used to develop and test
candidate type 2 diabetes precision medicine approaches,
ultimately, prospective trials, as done in cancer and mono-
genic diabetes (4,57,58), will likely be needed to demon-
strate clinical utility. TriMaster, an ongoing three-way
crossover randomized trial due to report in May 2021, is
one such study in type 2 diabetes (NCT02653209). Tri-
Master will directly test the hypotheses that simple sub-
groups defined by baseline BMI and eGFR alter response
with DPP-4i, SGLT2i, and TZD treatment (59). Not only will
this provide the first prospective randomized evaluation of
a precision medicine approach for glycemic response, the
three-way crossover design will allow an “n of 1” analysis of
patient preferences regarding the three treatments when
they are tried in randomized order in blinded conditions.
However, running prospective trials to test potential can-
didate factors one at a time for personalization is not
a feasible, cost-effective, or efficient strategy. Future trials
could instead test specific precision medicine algorithms
based on multiple factors (potentially both clinical and
genetic features), to test whether use of an algorithm
results in improved outcomes for patients. One simple
trial design for this would be to cluster randomize health
centers (e.g., general practitioner practices in the U.K.) to
either receive or not receive an algorithm—comparing
centers with and without the algorithm would enable
evaluation of its effectiveness and efficacy. If two com-
peting algorithms or strategies need to be tested, this
could be done using three-way cluster randomization.
A final key challenge is implementation of algorithms,
which, to ensure patient benefit, should be not only effective
but transparent, reproducible, and ethically sound (60) and
which should be equally and freely accessible to all health
professionals and patients. A type 2 diabetes treatment
selectionmodel would likely be most appropriately positioned
within clinical practice software systems, so that it can be
automatically populated with relevant clinical information
from the electronic health record and function as a decision
aid at the point of care. Development of software infrastruc-
ture that can utilize routinely collected health records to
support delivery of such probabilistic algorithms will be
required before precision medicine can truly become
a reality for common diseases such as type 2 diabetes.
CONCLUSIONS
Recent demonstration of robust, clinically relevant differ-
ences in glycemic response suggest that a precision med-
icine approach to selecting optimal type 2 diabetes treatment
will soon be possible. The most practical way to implement
this in the near future will be to focus on routine clinical
markers, and the most accurate approach will be integration
of continuous features into individualized, probabilistic pre-
dictionmodels that can be deployed at the point a decision to
escalate treatment is made, rather than subtyping. Estimates
of differences in treatment response can augment the limited
existing stratification of people with type 2 diabetes based on
cardiovascular and renal comorbidity andwill be applicable to
everyone requiring glucose-lowering treatment. For people
for whom differences in response between treatments are
modest, this information is still important, as it can facilitate
selection of treatment based on other criteria. A framework of
discovery in routine data, followed by replication and testing in
existing clinical trial data sets, offers a low-cost and principled
way to evaluate the potential of precision medicine, applicable
to other chronic diseases in addition to type 2 diabetes.
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